I get your point and I was wondering the same thing. I suppose it may come down to the science and potential. If it is that good, multiple labs may be interested and competition would push the price higher in AMBS favor. If GC has to solicit a partner then the partner holds the upper hand. I guess we'll have to wait and see what revenue guidance says to have a clearer picture.